These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
327 related articles for article (PubMed ID: 37021176)
1. European Stroke Organisation (ESO) Guidelines on Moyamoya angiopathy Endorsed by Vascular European Reference Network (VASCERN). Bersano A; Khan N; Fuentes B; Acerbi F; Canavero I; Tournier-Lasserve E; Vajcoczy P; Zedde ML; Hussain S; Lémeret S; Kraemer M; Herve D Eur Stroke J; 2023 Mar; 8(1):55-84. PubMed ID: 37021176 [TBL] [Abstract][Full Text] [Related]
2. European Stroke Organisation (ESO) guidelines on Primary Angiitis of the Central Nervous System (PACNS). Pascarella R; Antonenko K; Boulouis G; De Boysson H; Giannini C; Heldner MR; Kargiotis O; Nguyen TN; Rice CM; Salvarani C; Schmidt-Pogoda A; Strbian D; Hussain S; Zedde M Eur Stroke J; 2023 Dec; 8(4):842-879. PubMed ID: 37903069 [TBL] [Abstract][Full Text] [Related]
3. Clinical and Molecular Features of 5 European Multigenerational Families With Moyamoya Angiopathy. Grangeon L; Guey S; Schwitalla JC; Bergametti F; Arnould M; Corpechot M; Hadjadj J; Riant F; Aloui C; Drunat S; Vidaud D; Tournier-Lasserve E; Kraemer M Stroke; 2019 Apr; 50(4):789-796. PubMed ID: 30908154 [TBL] [Abstract][Full Text] [Related]
4. European Stroke Organisation (ESO) guideline on pharmacological interventions for long-term secondary prevention after ischaemic stroke or transient ischaemic attack. Dawson J; Béjot Y; Christensen LM; De Marchis GM; Dichgans M; Hagberg G; Heldner MR; Milionis H; Li L; Pezzella FR; Taylor Rowan M; Tiu C; Webb A Eur Stroke J; 2022 Sep; 7(3):I-II. PubMed ID: 36082250 [TBL] [Abstract][Full Text] [Related]
5. Clinical and Angiographic Features of Patients with Moyamoya Disease and the p.R4810K Heterozygous Variant. Zhang Q; Zhang D; Wang R; Liu Y; Zhang Y; Wang S; Zhao J World Neurosurg; 2016 Jun; 90():530-538.e3. PubMed ID: 26806063 [TBL] [Abstract][Full Text] [Related]
6. European Stroke Organisation and European Academy of Neurology joint guidelines on post-stroke cognitive impairment. Quinn TJ; Richard E; Teuschl Y; Gattringer T; Hafdi M; O'Brien JT; Merriman N; Gillebert C; Huyglier H; Verdelho A; Schmidt R; Ghaziani E; Forchammer H; Pendlebury ST; Bruffaerts R; Mijajlovic M; Drozdowska BA; Ball E; Markus HS Eur Stroke J; 2021 Sep; 6(3):I-XXXVIII. PubMed ID: 34746430 [TBL] [Abstract][Full Text] [Related]
7. European Stroke Organisation (ESO) guidelines on blood pressure management in acute ischaemic stroke and intracerebral haemorrhage. Sandset EC; Anderson CS; Bath PM; Christensen H; Fischer U; Gąsecki D; Lal A; Manning LS; Sacco S; Steiner T; Tsivgoulis G Eur Stroke J; 2021 Jun; 6(2):II. PubMed ID: 34780579 [TBL] [Abstract][Full Text] [Related]
8. European Stroke Organisation (ESO) guidelines on blood pressure management in acute ischaemic stroke and intracerebral haemorrhage. Sandset EC; Anderson CS; Bath PM; Christensen H; Fischer U; Gąsecki D; Lal A; Manning LS; Sacco S; Steiner T; Tsivgoulis G Eur Stroke J; 2021 Jun; 6(2):XLVIII-LXXXIX. PubMed ID: 34780578 [TBL] [Abstract][Full Text] [Related]
9. Importance of RNF213 polymorphism on clinical features and long-term outcome in moyamoya disease. Kim EH; Yum MS; Ra YS; Park JB; Ahn JS; Kim GH; Goo HW; Ko TS; Yoo HW J Neurosurg; 2016 May; 124(5):1221-7. PubMed ID: 26430847 [TBL] [Abstract][Full Text] [Related]
10. European Stroke Organisation (ESO) guidelines on intravenous thrombolysis for acute ischaemic stroke. Berge E; Whiteley W; Audebert H; De Marchis GM; Fonseca AC; Padiglioni C; de la Ossa NP; Strbian D; Tsivgoulis G; Turc G Eur Stroke J; 2021 Mar; 6(1):I-LXII. PubMed ID: 33817340 [TBL] [Abstract][Full Text] [Related]
11. European stroke organisation (ESO) guideline on cerebral small vessel disease, part 2, lacunar ischaemic stroke. Wardlaw JM; Chabriat H; de Leeuw FE; Debette S; Dichgans M; Doubal F; Jokinen H; Katsanos AH; Ornello R; Pantoni L; Pasi M; Pavlovic AM; Rudilosso S; Schmidt R; Staals J; Taylor-Rowan M; Hussain S; Lindgren AG Eur Stroke J; 2024 Mar; 9(1):5-68. PubMed ID: 38380638 [TBL] [Abstract][Full Text] [Related]
12. Mystery(n) Phenotypic Presentation in Europeans: Report of Three Further Novel Missense Santoro C; Mirone G; Zanobio M; Ranucci G; D'Amico A; Cicala D; Iascone M; Bernardo P; Piccolo V; Ronchi A; Limongelli G; Carotenuto M; Nigro V; Cinalli G; Piluso G Int J Mol Sci; 2022 Aug; 23(16):. PubMed ID: 36012218 [TBL] [Abstract][Full Text] [Related]
13. Rare RNF213 variants in the C-terminal region encompassing the RING-finger domain are associated with moyamoya angiopathy in Caucasians. Guey S; Kraemer M; Hervé D; Ludwig T; Kossorotoff M; Bergametti F; Schwitalla JC; Choi S; Broseus L; Callebaut I; Genin E; Tournier-Lasserve E; Eur J Hum Genet; 2017 Aug; 25(8):995-1003. PubMed ID: 28635953 [TBL] [Abstract][Full Text] [Related]
14. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas. Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557 [TBL] [Abstract][Full Text] [Related]
15. The genetic landscape and clinical implication of pediatric Moyamoya angiopathy in an international cohort. Zanoni P; Steindl K; Sticht H; Oneda B; Joset P; Ivanovski I; Horn AHC; Cabello EM; Laube J; Zweier M; Baumer A; Rauch A; Khan N Eur J Hum Genet; 2023 Jul; 31(7):784-792. PubMed ID: 37012328 [TBL] [Abstract][Full Text] [Related]
16. Genotype-Phenotype Correlation in Long-Term Cohort of Japanese Patients with Moyamoya Disease. Nomura S; Yamaguchi K; Akagawa H; Kawashima A; Moteki Y; Ishikawa T; Aihara Y; Saito T; Okada Y; Kawamata T Cerebrovasc Dis; 2019; 47(3-4):105-111. PubMed ID: 30947170 [TBL] [Abstract][Full Text] [Related]
17. European Stroke Organisation and European Academy of Neurology joint guidelines on post-stroke cognitive impairment. Quinn TJ; Richard E; Teuschl Y; Gattringer T; Hafdi M; O'Brien JT; Merriman N; Gillebert C; Huygelier H; Verdelho A; Schmidt R; Ghaziani E; Forchammer H; Pendlebury ST; Bruffaerts R; Mijajlovic M; Drozdowska BA; Ball E; Markus HS Eur J Neurol; 2021 Dec; 28(12):3883-3920. PubMed ID: 34476868 [TBL] [Abstract][Full Text] [Related]
18. Clinical Features and Surgical Outcomes of Patients With Moyamoya Disease and the Homozygous RNF213 p.R4810K Variant. Zhang Q; Ge P; Ma Y; Zhang D; Wang R; Zhang Y; Wang S; Cao Y; Zhao M; Zhao J J Child Neurol; 2019 Nov; 34(13):793-800. PubMed ID: 31290353 [TBL] [Abstract][Full Text] [Related]
19. Absence of the RNF213 p.R4810K variant may indicate a severe form of pediatric moyamoya disease in Japanese patients. Hara S; Mukawa M; Akagawa H; Thamamongood T; Inaji M; Tanaka Y; Maehara T; Kasuya H; Nariai T J Neurosurg Pediatr; 2022 Jan; 29(1):48-56. PubMed ID: 34624841 [TBL] [Abstract][Full Text] [Related]
20. Impact of RNF213 founder polymorphism (p.R4810K) on the postoperative development of indirect pial synangiosis after direct/indirect combined revascularization surgery for adult Moyamoya disease. Ito M; Kawabori M; Sugiyama T; Tokairin K; Tatezawa R; Uchino H; Kazumata K; Houkin K; Fujimura M Neurosurg Rev; 2022 Jun; 45(3):2305-2313. PubMed ID: 35128622 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]